Athersys Stock Price - ATHX

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Level 1 Starter
Monthly Subscription
for only
$15.87
VAT not included
After Hours
Last Trade
Last $ 1.24 ◊ 0.00 (0.00%)
Company Name Stock Ticker Symbol Market Type
Athersys Inc ATHX NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.05 -3.88% 1.24 1.30 1.23 1.29 1.29 20:00:00
Bid Price Ask Price Spread Spread % News
1.21 1.50 0.29 19.33% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
2,040 531,711 $ 1.26 $ 668,976 513,674 1.00 - 2.06
Last Trade Time Type Quantity Stock Price Currency
17:10:36 formt 152 $ 1.24 USD

Athersys Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 194.27M 156.67M $ -24.28M -0.18 - 152.66M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% -5.00 2.60%

more financials information »

Athersys News

Loading Messages....

Latest ATHX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ATHX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.301.351.231.29502,885-0.06-4.62%
1 Month1.381.481.001.34463,624-0.14-10.14%
3 Months1.441.491.001.34447,149-0.20-13.89%
6 Months1.581.891.001.43514,392-0.34-21.52%
1 Year2.012.061.001.53591,973-0.77-38.31%
3 Years1.593.091.001.74744,733-0.35-22.01%
5 Years1.343.430.901.81738,547-0.10-7.46%

Athersys Description

Athersys Inc is a clinical stage biotechnology company. It is focused on developing novel and proprietary therapies in the areas where there is significant unmet medical need, particularly in the regenerative medicine area. The firm's main product is Multistem cell therapy. Its current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.